AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33121471
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus Metformin (100 mg aspirin and 250 mg metformin for 8 weeks)
Trial: 33121471
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus Placebo (100 mg aspirin and placebo for 8 weeks)
Trial: 36372695
Drug: Probiotic (Lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic (Lactobacillus ruteri, 100 mg)
Trial: 37824257
Drug: Motivational enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational enhancement therapy (MET)
Trial: 33947668
Drug: Home medicines
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home medicines review (HMR) and home-based pulmonary rehabilitation (HomeBase) for COPD patients
Trial: 33499659
Drug: TF-CBT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TF-CBT with adjunctive AAT (TF-CBT+AAT)
Trial: 33478749
Drug: Rapid induction
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid induction (RI) with TCI of propofol effect‐site (CeCALC) 5.4μg/mL (modified Marsh model)
Trial: 33478749
Drug: Slow induction
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow induction (SI) with propofol infusion of 10mg/kg/hour
Trial: 33206752
Drug: Colonoscopy after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colonoscopy after 3 hours of colon preparation with 10% mannitol
Trial: 33206752
Drug: Colonoscopy after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colonoscopy after 6 hours of colon preparation with 10% mannitol
Trial: 33206752
Drug: Colonoscopy after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colonoscopy after 3 hours of colon preparation with 10% mannitol in patients with diabetes mellitus
Trial: 37492067
Drug: Naltrexone (opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (opioid antagonist)
Trial: 35580976
Drug: Anifrolumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anifrolumab (300 mg every 4 weeks for 48 weeks)
Trial: 32764887
Drug: BD-TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BD-TAP block with 3 mg/kg of ropivacaine diluted to 60 mL
Trial: 34568362
Drug: Esketamine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine (0.1 mg/kg bolus after anesthesia induction, 0.1 mg/kg/h during operation, 0.015 mg/kg/h in PCIA after surgery)
Trial: 33380574
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural injections with 1% lidocaine hydrochloride mixed with triamcinolone
Trial: 34134591
Drug: Placebo (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (300 mg of corn-starch)
Trial: 32231364
Drug: Integrative Adapt
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative Adapt Therapy (IAT)
Trial: 33932990
Drug: Theophylline infusion
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline infusion (Group T)
Trial: 33932990
Drug: GLP-1 +
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 + Theophylline infusion (Group GT)
Trial: 33222710
Drug: Treatment phase
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment phase without hospitalisation
Trial: 33222710
Drug: Treatment phase
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment phase without fever
Trial: 33222710
Drug: Treatment phase
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment phase with ≤ 2 episodes of diarrhoea
Trial: 32488885
Drug: Trazodone 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone 20 mg
Trial: 32488885
Drug: Trazodone 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone 60 mg
Trial: 32488885
Drug: Trazodone 140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone 140 mg
Trial: 34444703
Drug: β-alanine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-alanine (20 g per day for 7 days)
Trial: 38102535
Drug: eptinezumab 100
RxNorm normalized name: EPTINEZUMAB 100 mg in 1 mL INTRAVENOUS INJECTION [Vyepti]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eptinezumab 100 mg
Trial: 34088322
Drug: L-tyrosine-adsorbed allergen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tyrosine-adsorbed allergen extracts
Trial: 39222277
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg once daily)
Trial: 35316372
Drug: 6-week supervised
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6-week supervised concurrent chair-based exercise program (stretching, strength, balance exercises, aerobic dance; 5 days/week, 30-40 min/day, 2 workouts/day lasted 15-20 min)
Trial: 35770308
Drug: Patient satisfaction
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient satisfaction levels after treatment in Area A (Fractional Er: YAG)
Trial: 32623977
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure-lowering therapy (target systolic BP, 110-139 mm Hg)
Trial: 32623977
Drug: Standard blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard blood pressure-lowering therapy (target systolic BP, 140-179 mm Hg)
Trial: 36521773
Drug: Acupuncture intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acupuncture intervention combined with pharmacologic treatment
Trial: 35719024
Drug: Family Focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family Focused Therapy (FFT-CHR)
Trial: 33648576
Drug: Blended cognitive
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended cognitive behaviour therapy (PowerMe intervention) targeting fatigue, tailored to individual treatment plans, duration of 33 weeks with a baseline period of 5 to 9 weeks before intervention.
Trial: 38492517
Drug: Medication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication therapy
Trial: 33035763
Drug: Monthly oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly oral health intervention by dental hygienists for 8 months
Trial: 33378108
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (electroacupuncture at Hegu point (LI4) and Zusanli point (ST36) and auricular-point pressure on Shenmen point)
Trial: 33378108
Drug: Single therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single therapy (only auricular-point pressure)
Trial: 34373384
Drug: DKT therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DKT therapy group
Trial: 33459698
Drug: Cupping therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cupping therapy with 45 mm cup
Trial: 32221707
Drug: Arm immobilization
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm immobilization without MI treatment
Trial: 32310966
Drug: Community-wide mass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-wide mass drug administration (MDA) for STH
Trial: 35237860
Drug: Drug-coated balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-coated balloon angioplasty (DCBA)
Trial: 34217297
Drug: IVIG administered
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG administered over 12 hours (12H group)
Trial: 34217297
Drug: IVIG administered
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG administered over 24 hours (24H group)
Trial: 34872087
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia + Circadian Rhythm Support (CBT-I+CRS)
Trial: 33939347
Drug: Antihistamine +
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine + Probiotic (LactoCare)
Trial: 33939347
Drug: Antihistamine (Control)
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine (Control)
Trial: 35924398
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral hygiene regimen
Trial: 32801436
Drug: EECP Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EECP Therapy
Trial: 32801436
Drug: TMZ 35
RxNorm normalized name: TMZ
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TMZ 35 mg twice daily + EECP Therapy
Trial: 33896356
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg/2 mL pre-filled syringe
Trial: 36917429
Drug: Self-Injection Assessment
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-Injection Assessment Questionnaire (SIAQ)
Trial: 39223617
Drug: treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment as usual (TAU)
Trial: 34471708
Drug: Positive psychology
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive psychology interventions (PPI) - 10 weekly training sessions
Trial: 36167851
Drug: Opt-out protocol
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Opt-out protocol for antibiotic de-escalation
Trial: 33078727
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg and amoxicillin 1 g bid during the early half of treatment, followed by esomeprazole 40 mg with levofloxacin 500 mg and tinidazole 500 mg bid during the second half of treatment (Group A)
Trial: 33078727
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg and amoxicillin 1 g bid during the early half of treatment, followed by esomeprazole 40 mg with clarithromycin 500 mg bid during the second half of treatment (Group B)
Trial: 34369902
Drug: olanzapine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olanzapine (10 mg) + placebo
Trial: 34369902
Drug: olanzapine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olanzapine (10 mg) + miricorilant (600 mg)
Trial: 33125405
Drug: Intraoperative substitution
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative substitution of volume and other co-medications
Trial: 33911859
Drug: Ensifentrine 0.375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensifentrine 0.375 mg + tiotropium
Trial: 32306982
Drug: Routine Veterans
RxNorm normalized name: benzalkonium chloride Topical Foam [Veteran Shield 24]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine Veterans Health Administration (VHA) primary care
Trial: 34890830
Drug: Surface treatment
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surface treatment of materials
Trial: 615918851
Drug: Dexamethasone intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone intravitreal implant (Ozurdex)
Trial: 34871104
Drug: hu14.18K322A with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hu14.18K322A with induction chemotherapy
Trial: 36335783
Drug: Regorafenib 120
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 120 mg QD (arm B)
Trial: 36335783
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg QD 1 week on/1 week off (arm C)
Trial: 32668474
Drug: Radiotherapy (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy (median dose of 59.4Gy within 2 months after ESD)
Trial: 34379996
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (maintained usual activities of daily living)
Trial: 32766779
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (3 sessions of physical therapy including desensitization maneuvers and tendon/nerve gliding exercise program)
Trial: 33572618
Drug: Early physiotherapy
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early physiotherapy program (functional exercises, scar manual therapy, educational tips)
Trial: 33740922
Drug: Equine-Assisted Activities
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equine-Assisted Activities (EAA), 40-minute sessions twice a week for 16 weeks.
Trial: 33740922
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (daily life without special treatments).
Trial: 32605909
Drug: Standard-dose pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose pembrolizumab (2 mg/kg amended to 200 mg) plus reduced-dose ipilimumab (1 mg/kg) every 3 weeks for four cycles, then pembrolizumab alone for up to 2 years
Trial: 32535646
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg intravenous adrenaline
Trial: 35126620
Drug: Shuangshen Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuangshen Decoction combined with immunological preparations
Trial: 35126620
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment and immune agents (routine group)
Trial: 33626166
Drug: Prompt treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt treatment (≤ 6 days)
Trial: 33626166
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment (> 10 days)
Trial: 33646447
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral steroid dose of >10 mg
Trial: 33646447
Drug: Other immunosuppressants
RxNorm normalized name: Other immunosuppressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other immunosuppressants (injected steroids, cyclophosphamide, biological agents, methotrexate, cyclosporine)
Trial: 32720384
Drug: High-dose omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose omega-3 icosapent ethyl
Trial: 98327681
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral tolcapone
Trial: 98327681
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg intravenous tolcapone
Trial: 36284318
Drug: Dabigatran (110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran (110 or 150 mg twice daily)
Trial: 33693475
Drug: Adaptive designs,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive designs, master protocols, drug repurposing, in silico trials, N-of-1 trials
Trial: 32860005
Drug: Forsythin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forsythin (single oral administration)
Trial: 37741105
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonists
Trial: 34936232
Drug: Hydrocodone/acetaminophen (APAP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone/acetaminophen (APAP)
Trial: 34842189
Drug: Oral type
RxNorm normalized name: adenovirus vaccine live oral type-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral type 1 IFN
Trial: 36256646
Drug: unadjuvanted vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: unadjuvanted vaccine 15μg H7N9
Trial: 34609452
Drug: Subcutaneous scopolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous scopolamine butylbromide
Trial: 39025785
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg
Trial: 39025785
Drug: Ticagrelor 60
RxNorm normalized name: ticagrelor 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 60 mg
Trial: 35852024
Drug: Smaller glasses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smaller glasses (290 ml)
Trial: 35852024
Drug: Larger glasses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larger glasses (370 ml)
Trial: 34391263
Drug: Finding-oriented manual
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finding-oriented manual therapy techniques (MTT), 9 treatments over a three-week period
Trial: 35945582
Drug: Online self-help
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Online self-help intervention based on Acceptance and Commitment Therapy (ACT) for 8 weeks with therapeutic email guidance
Trial: 32345348
Drug: Intense regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intense regimen of 12-h IO-therapy per day for 4 weeks
Trial: 32345348
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen of 4-h IO-therapy per day for 12 weeks
Trial: 35524938
Drug: Buprenorphine buccal
RxNorm normalized name: buprenorphine Buccal Film
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine buccal film (BBF) 900 µg
Trial: 34587383
Drug: REGEN-COV 2400-mg
RxNorm normalized name: casirivimab
DrugBank: Casirivimab (DB15941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: REGEN-COV 2400-mg and 1200-mg
Trial: 34587383
Drug: REGEN-COV 2400-mg
RxNorm normalized name: casirivimab
DrugBank: Casirivimab (DB15941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: REGEN-COV 2400-mg
Trial: 34819266
Drug: Durvalumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab + chemotherapy (platinum-based, ≤4 cycles) prior to surgery, followed by durvalumab monotherapy (q4w, for an additional 12 cycles post surgery)
Trial: 34819266
Drug: Durvalumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab + chemotherapy
Trial: 38227033
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + chemotherapy
Trial: 32520820
Drug: Hybrid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid treatment
Trial: 33530511
Drug: Calcifediol weekly
RxNorm normalized name: Calcifediol
DrugBank: Calcifediol (DB00146)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcifediol weekly oral dose
Trial: 33530511
Drug: Weekly cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly cholecalciferol
Trial: 39668137
Drug: Olaparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (300 mg twice daily)
Trial: 32565595
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g hydroalcoholic extract of Fenugreek seeds daily for 3 months
Trial: 33630646
Drug: CDP-Choline 500
RxNorm normalized name: CDP-choline
DrugBank: Citicoline (DB12153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP-Choline 500 mg
Trial: 33630646
Drug: CDP-Choline 1000
RxNorm normalized name: CDP-choline
DrugBank: Citicoline (DB12153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP-Choline 1000 mg
Trial: 33630646
Drug: CDP-Choline 2000
RxNorm normalized name: CDP-choline
DrugBank: Citicoline (DB12153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP-Choline 2000 mg
Trial: 32000790
Drug: Arm-specific treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm-specific treatment delivered by a physiotherapist (Control Group)
Trial: 36244828
Drug: Pattern of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pattern of CA-125 change following chemotherapy cycle 1
Trial: 36068494
Drug: eptinezumab 100
RxNorm normalized name: EPTINEZUMAB 100 mg in 1 mL INTRAVENOUS INJECTION [Vyepti]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eptinezumab 100 mg or 300 mg, administered intravenously once every 12 weeks for up to two doses
Trial: 33961539
Drug: Message recommending
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Message recommending fewer doses at age 11–12
Trial: 33961539
Drug: Message recommending
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Message recommending fewer doses before age 15